By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

The FDA approves blood test to guide breast cancer therapy by detecting ESR1 mutations for targeted treatment selection.

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

CRANBURY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- OncLive ®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum supporter), Daiichi-Sankyo (platinum supporter) and ...